GRAIL, Inc. operates as a biotechnology company. The Company focuses on combining science, technology, and clinical studies to reveal cancer at its beginings. GRAIL offers its services in the United States.

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-12)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

GRAIL (GRAL US)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-12)

Current Report (Form 8-K | Period ending 2024-10-21)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)